Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $25.00 | Outperform | Wolfe Research |
| 1/30/2026 | $30.00 | Buy | Jefferies |
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET Location: Boston, MA Webcast Link: TD Cowen 46th Annual Health Care Conference Jefferies Biotech on the Beach Summit Date: Tuesday, March 10, 2026 Location: Miami Beach, FL Leerink Partner
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium
Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation
Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00
Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)
8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation